Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of VX-993 in Healthy Adults
NCT06226454Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VX-993 in pain (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Jan 2024; status: completed.
02
Drugs
VX-993
03
Conditions
pain
Beyond the preview
Go deeper on NCT06226454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06226454.